Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

2.

Antithrombin Chicago, amino acid substitution of arginine 393 to histidine.

Erdjument H, Lane DA, Panico M, Di Marzo V, Morris HR, Bauer K, Rosenberg RD.

Thromb Res. 1989 Jun 15;54(6):613-9.

PMID:
2781509
3.

Antithrombin Milano, single amino acid substitution at the reactive site, Arg393 to Cys.

Erdjument H, Lane DA, Ireland H, Di Marzo V, Panico M, Morris HR, Tripodi A, Mannucci PM.

Thromb Haemost. 1988 Dec 22;60(3):471-5.

PMID:
3238650
4.

A novel amino acid substitution in the reactive site of a congenital variant antithrombin. Antithrombin pescara, ARG393 to pro, caused by a CGT to CCT mutation.

Lane DA, Erdjument H, Thompson E, Panico M, Di Marzo V, Morris HR, Leone G, De Stefano V, Thein SL.

J Biol Chem. 1989 Jun 15;264(17):10200-4.

5.

Antithrombin Sheffield: amino acid substitution at the reactive site (Arg393 to His) causing thrombosis.

Lane DA, Erdjument H, Flynn A, Di Marzo V, Panico M, Morris HR, Greaves M, Dolan G, Preston FE.

Br J Haematol. 1989 Jan;71(1):91-6.

PMID:
2917133
6.

Formation of a covalent disulfide-linked antithrombin-albumin complex by an antithrombin variant, antithrombin "Northwick Park".

Erdjument H, Lane DA, Ireland H, Panico M, Di Marzo V, Blench I, Morris HR.

J Biol Chem. 1987 Oct 5;262(28):13381-4.

8.

Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability.

Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N.

Proc Natl Acad Sci U S A. 1984 Jan;81(2):289-93.

9.

Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His.

Owen MC, Borg JY, Soria C, Soria J, Caen J, Carrell RW.

Blood. 1987 May;69(5):1275-9.

10.

Antithrombin-III Denver, a reactive site variant.

Stephens AW, Thalley BS, Hirs CH.

J Biol Chem. 1987 Jan 25;262(3):1044-8.

12.

Functional antithrombin-III variant (41 Pro----Leu) identified by liquid secondary ion mass spectrometry.

Brennan SO, Borg JY, Shaw GJ, Caen J, George PM.

Pathology. 1991 Jan;23(1):1-4.

PMID:
2062560
13.

Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate.

Caso R, Lane DA, Thompson EA, Olds RJ, Thein SL, Panico M, Blench I, Morris HR, Freyssinet JM, Aiach M, et al.

Br J Haematol. 1991 Jan;77(1):87-92.

PMID:
1998601
14.
16.

Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin.

Okajima K, Abe H, Wagatsuma M, Okabe H, Takatsuki K.

Am J Hematol. 1995 Jan;48(1):12-8.

PMID:
7832187
17.

Formylated peptides from cyanogen bromide digests identified by fast atom bombardment mass spectrometry.

Goodlett DR, Armstrong FB, Creech RJ, van Breemen RB.

Anal Biochem. 1990 Apr;186(1):116-20.

PMID:
2356963
18.

Antithrombin III "Northwick Park": a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity.

Howarth DJ, Samson D, Stirling Y, Seghatchian MJ.

Thromb Haemost. 1985 Jun 24;53(3):314-9.

PMID:
4049307
19.
20.

Molecular defect of prothrombin Barcelona. Substitution of cysteine for arginine at residue 273.

Rabiet MJ, Furie BC, Furie B.

J Biol Chem. 1986 Nov 15;261(32):15045-8.

Supplemental Content

Support Center